Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study

NCT00409175 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00409175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00409175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2007
Completion date
May 31, 2009
Enrollment
128 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

familial amyloid polyneuropathy